News
44m
InvestorsHub on MSNAltimmune Shares Slide 37% Despite Hitting Key MASH Trial GoalsAltimmune Inc. (NASDAQ:ALT) saw its stock tumble by 37% after releasing topline data from its Phase 2b IMPACT trial ...
From the outset, the cast of the television series MASH was a solid ensemble of performers, led by Alan Alda, who ...
9h
Stocktwits on MSNAltimmune Stock Runs Hot Ahead Of MASH Trial Readout; Retail Bulls Eye Big WinAltimmune shares jumped during after-hours trading on Wednesday after the biotech firm said it would disclose top-line ...
First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis ...
The clinical-stage biopharmaceutical company reported that the trial met its primary endpoint, with up to 59.1% of participants achieving MASH resolution without worsening of fibrosis in an ...
Madrigal Pharma's REZDIFFRA sees 33% Q1 2025 sales growth, strong EU progress, and promising MASH data. Read why I maintain ...
Rivus Pharmaceuticals’ fat-busting, muscle-sparing drug candidate reduced liver fat in a phase 2 trial while showcasing the ...
9don MSN
Paramount Pictures has acquired an original comedic pitch, inspired by the classic game MASH, from Emmy, Grammy, and Golden ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results